Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214174 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
A Phase 2 study, sponsored by ICON Bioscience.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01214174: Clinical Trial Phase 2 study, sponsored by ICON Bioscience.
NCT01214174 is a Phase 2 study that was terminated before completion, run by ICON Bioscience. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01214174, a Phase 2 study, was terminated before completion, sponsored by ICON Bioscience.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.
Primary Outcome
This study will measure as its primary endpoint the anterior chamber cell count at Day 8 post-treatment in the study eye. The proportion of patients with anterior chamber cell count = 0 at Day 8 in the study eye for each dosage group will be compared. Only one eye was treated per participant.
Interventions
- DRUG IBI-10090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Why NCT01214174 stopped before completion
NCT01214174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which IBI-10090 is the first listed.
NCT01214174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01214174 about?
NCT01214174 is a clinical study titled "Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients". This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.
What is the current status of trial NCT01214174?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2010-10. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01214174?
The interventions under investigation include: IBI-10090 (DRUG).
Who is sponsoring clinical trial NCT01214174?
This trial is sponsored by ICON Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01214174's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia